TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.
TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $960 to $980.